AC
AKRO

Allstate Corporation’s Akero Therapeutics AKRO Stock Holding History

Allstate Corporation’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-8,384
Closed -$208K – 691
2021
Q2 		$208K Buy
8,384
+97
+1% +$2.73K 0.01% 706
2021
Q1 		$240K Buy
+8,287
New +$251K 0.01% 689

Other funds holding AKRO

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
YCM
Yiheng Capital Management San Francisco, California $231M AUM 29.07% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Allstate Corporation's AKRO Position: Q3 2021 in Review

Allstate Corporation sold out of Akero Therapeutics (AKRO) in Q3 2021, closing a stake of 8,384 shares — an estimated $208K sold.

Allstate Corporation first reported a position in AKRO in Q1 2021 and held it in 2 quarters. The position peaked at $240K in Q1 2021. 103 funds tracked by Wall St. Rank hold AKRO as of Q3 2021.

  • Allstate Corporation reported no remaining Akero Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Allstate Corporation sold 8,384 Akero Therapeutics shares in Q3 2021, an estimated $208K.
  • Allstate Corporation first reported a position in Akero Therapeutics in Q1 2021 and held it in 2 quarters.
  • Allstate Corporation's Akero Therapeutics position peaked at $240K in Q1 2021.
  • 103 funds tracked by Wall St. Rank held Akero Therapeutics as of Q3 2021.

Based on Allstate Corporation's 13F filing for Q3 2021, filed 15 Nov 2021.